

20. Heekstra OS, Ossenkuppele GJ, Golding R, et al. Early treatment response in malignant lymphoma as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy. *J Nucl Med* 1993;34:1706-1710.
21. Newman JS, Francis IR, Kaminski MS, et al. Imaging of lymphoma with PET with 2-[¹⁸F]-fluoro-2-deoxyglucose: correlation with CT. *Radiology* 1994;190:111-116.
22. Iosilevsky G, Front D, Betman L, et al. Uptake of ⁶⁷Ga-citrate and ²H-3-deoxyglucose in the tumor model following chemotherapy and radiotherapy. *J Nucl Med* 1985;26:278-283.
23. Fishman AJ, Strauss WH. When magic bullets ricochet [Editorial]. *J Nucl Med* 1990;31:32-33.
24. Juni JE. Taking brain SPECT seriously: reflections on recent clinical reports [Commentary]. *J Nucl Med* 1994;35:1891-1895.
25. Anderson KC, Leonard RCF, Canellos GP, et al. High-dose gallium imaging in lymphoma. *Am J Med* 1983;75:327-331.
26. Tumeh SS, Rosenthal DS, Kaplan WD, et al. Lymphoma: evaluation with ⁶⁷Ga SPECT. *Radiology* 1987;164:111-113.
27. Israel O, Jerushalmi J, Ben-Haim S, et al. Normal and abnormal ⁶⁷Ga SPECT anatomy in patients with lymphoma. *Clin Nucl Med* 1990;15:334-345.
28. Front D, Bar-Shalom R, Iosilevsky G, et al. Gallium-67 scintigraphy with a dual-head camera. *Clin Nucl Med* 1995;20:542-548.
29. Canellos GP. Residual mass in lymphoma may not be residual disease [Editorial]. *J Clin Oncol* 1988;6:931-932.
30. Weeks JC, Yeap BY, Canellos GP, et al. Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission. *J Clin Oncol* 1991;9:1196-1203.
31. Surborne A, Longo D, De Vita V, et al. Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management. *J Clin Oncol* 1988;6:1832-1837.
32. Champion PE, Groshar D, Hooper HR, et al. Does gallium uptake in the pulmonary hila predict involvement by non-Hodgkin's lymphoma? *Nucl Med Commun* 1992;13:730-737.
33. Israel O, Front D. Benign mediastinal and parahilar uptake of gallium-67 in treated lymphoma: do we have all the answers? [Editorial]. *J Nucl Med* 1993;34:1330-1333.
34. Catane R, Catane H, Rozenzweig M. Cancer therapy—economic aspects. *Harefuah* 1995;128:182-185.
35. Hornberger JC, Redelmeier DA, Petersen J. Variability among methods to assess patients' well-being and consequent effect on a cost-effectiveness analysis. *J Clin Epidemiol* 1992;45:505-512.
36. Culyer AJ, Jonsson B. Ought cancer treatments to be immune from socio-economic evaluation? An epilogue. *Eur J Cancer* 1991;29A:S31-S32.
37. Hillner BE, Smith TJ. Efficacy and cost-effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. *N Engl J Med* 1991;324:160-168.
38. Grilli R, Oxamn AD, Julian JA. Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? *J Clin Oncol* 1993;11:1866-1872.

CORRECTION

In the *JNM* December 1995 Table of Contents, the title of the article by Volkow et al. (page 2162) was printed incorrectly. The correct title is, "A New PET Ligand for the Dopamine Transporter: Studies in the Human Brain."